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The detection of germline mutations in BRCA1 and BRCA2 is essential to the formulation of clinical 
management strategies, and in Brazil, there is limited access to these services, mainly due to the costs/
availability of genetic testing. Aiming at the identification of recurrent mutations that could be included 
in a low-cost mutation panel, used as a first screening approach, we compiled the testing reports of 
649 probands with pathogenic/likely pathogenic variants referred to 28 public and private health care 
centers distributed across 11 Brazilian States. Overall, 126 and 103 distinct mutations were identified 
in BRCA1 and BRCA2, respectively. Twenty-six novel variants were reported from both genes, and 
BRCA2 showed higher mutational heterogeneity. Some recurrent mutations were reported exclusively 
in certain geographic regions, suggesting a founder effect. Our findings confirm that there is significant 
molecular heterogeneity in these genes among Brazilian carriers, while also suggesting that this 
heterogeneity precludes the use of screening protocols that include recurrent mutation testing only. 
This is the first study to show that profiles of recurrent mutations may be unique to different Brazilian 
regions. These data should be explored in larger regional cohorts to determine if screening with a panel 
of recurrent mutations would be effective.
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BRCA1 and BRCA2 are tumor suppressor genes and their protein products play an important role in the repair of 
DNA double-strand breaks through homologous recombination (HR)1. Individuals harboring germline patho-
genic variants in BRCA1 and BRCA2 (BRCA) are strongly predisposed to the development of breast (BC; lifetime 
risk up to 85% and 45%, respectively) and ovarian cancers (OC; lifetime risk up to 39% and 11%, respectively)2 
as well as other solid tumors3. As bona fide tumor-suppressor genes, the wild-type allele is frequently lost (mainly 
through loss of heterozygosity) during tumorigenesis, thereby becoming completely inactivated in the tumor4. 
Tumors arising within the context of a complete loss of BRCA function are amenable to treatment with agents 
targeting HR DNA repair deficiency, such as poly(ADP) ribose polymerase (PARP) inhibitors (PARPi) and 
platinum-based chemotherapy5. In the past few years, these drugs have shown to be effective in the treatment of 
advanced ovarian cancer in patients harboring somatic and/or germline BRCA mutations6,7, and more recently, 
the FDA extended the approval of PARPi in the BC BRCA-related metastatic clinical setting8,9. These approvals 
will benefit many patients since BRCA mutations are identified in 8–13% of all ovarian cancer cases10, and approx-
imately 10% of breast cancers11, which is the most common cancer type among women worldwide and also in 
Brazil12,13.
Considering this scenario, the identification of a BRCA mutation is of paramount importance not only for pro-
viding appropriate genetic counseling and discussing risk-reducing interventions, but also for determining treat-
ment options in patients with metastatic disease. A challenge in the identification of carriers in Latin America, 
however, is the limited availability of cancer risk evaluation programs and genetic testing per se. In Brazil, 70–80% 
of the population relies on the public health care system14, which does not provide genetic testing. Consequently, 
the mutational profile of BRCA remains largely unknown. Systematic testing of at-risk individuals brings knowl-
edge of the genetic background of a population, and may enable the identification of multiple recurrent and/or 
founder mutations, which, in turn, would support the use of mutation panels as a first-line screening tool.
In this study, we aimed to describe the landscape of BRCA germline mutations in Brazil and investigate if the 
use of a panel of recurrent mutations would be useful in this population.
Results
A total of 649 reports of pathogenic/likely pathogenic variants were retrieved from 28 centers in 11 different 
Brazilian States. As shown in Fig. 1, the majority of reports was obtained from the State of São Paulo (60.1%), 
which is also the State with the largest number of participating centers (N = 7). The second largest number of 
reports was obtained from the State of Rio Grande do Sul (16.5%).
The most common types of pathogenic variants identified in both genes were small deletions and single nucle-
otide variants (SNVs), and are predicted to result in frameshift and non-sense alterations in the protein sequence 
(Fig. 2). Synonymous pathogenic variants were identified only once in each gene, in two distinct patients: BRCA1 
c.4185G>A and the BRCA2 c.9117G>A. Large genomic rearrangements (LGR) were present in 4.9% of all cases, 
and among them, the BRCA2 c.156_157insAlu corresponded to 34.3% of all LGRs. The frequency of each type of 
variant and their molecular consequences are depicted in Fig. 2A,B, respectively.
As shown in Table 1, 126 distinct pathogenic BRCA1 variants were identified among 441 probands, corre-
sponding to 68% (441/649) of all reported mutations. Among these, a subset of 33 distinct BRCA1 mutations cor-
responded to 73.4% of all variants identified in this gene. The nine most prevalent BRCA1 mutations accounted 
for 50.3% of all BRCA1 reported mutations, and among these, the European founder mutation c.5266dupC (for-
merly known as 5382insC) was the most common, corresponding to 20.2% of all variants found in BRCA1. In 
BRCA2, 103 distinct variants were identified in 208 probands, corresponding to 32% of all individuals tested 
(Table 2). The mutational profile of BRCA2 was more heterogeneous, since non-recurring mutations (those seen 
only once) were more common (35.1%) than in BRCA1 (15.4%). Moreover, a higher frequency of novel vari-
ants was identified in BRCA2 (17/103) when compared to BRCA1 (9/126). Figures 3 and 4 show all reported 
BRCA1 and BRCA2 mutations, respectively, including LGR in both genes. Detailed information about BRCA1 
and BRCA2 mutations (predicted protein change, rs number and overall frequency) are summarized in the 
Supplementary Dataset.
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Although the most common mutation, BRCA1 c.5266dupC, was reported in all geographical regions, some 
recurrent BRCA1 mutations (detected in three or more individuals) seem to be unique to a particular Brazilian 
State. The variants c.188 T>A, c.2405_2406delTG, c.3916_3917delTT, c.689_692delAGAC, c.4287C>A, and 
c.5123C>A were reported exclusively among individuals recruited from the State of São Paulo (Southeastern 
region). In addition, the c.1039_1040delCT and c.1039delC variants were reported exclusively in the State of 
Pará (Northern region), while c.3598C>T and c.5177_5180delGAAA were only reported in pathogenic mutation 
carriers from the State of Rio Grande do Sul (Southern Region). No similar trends were observed among BRCA2 
recurrent mutations.
When considering all BRCA1 and BRCA2 mutations seen in three or more individuals, a subset of 51 variants 
(33 in BRCA1 and 18 in BRCA2), accounted for 67% of all reports. In a more stringent scenario, mutations seen 
in four or more individuals, totaling 30 variants (23 in BRCA1 and 7 in BRCA2) corresponded to 57.3% of all 
mutations.
Discussion
Many factors affect the probability of developing breast or ovarian cancer, but no predictor is as determinant 
and prevalent as the inheritance of a BRCA mutation. There are several clinical management options for indi-
viduals harboring BRCA mutations, including risk reducing surgeries (bilateral risk-reducing mastectomy, 
salpingo-oophorectomy)15, chemoprevention16 and intensive surveillance with annual breast magnetic resonance 
imaging17. Several studies have demonstrated that, after identifying a BRCA-mutation carrier, genetic counseling 
and testing of at-risk individuals results in increased surveillance and use of risk-reduction strategies ultimately 
leading to primary or secondary prevention of cancer and improved outcomes in carriers18. Despite these benefits 
there is limited availability of genetic testing in Latin American countries, including Brazil14,19.
Low cost screening panels including recurrent BRCA pathogenic variants (e.g. Ashkenazi Jewish Panel) 
have been used in certain countries/populations as an initial approach to overcome technical and economical 
Figure 1. Geographical distribution of HBOC patients with pathogenic and likely pathogenic BRCA1 and 
BRCA2 variants in Brazil (N = 649). Legends represent the Brazilian States of Amazonas (AM), Pará (PA), Ceará 
(CE), Rio Grande do Norte (RN), Bahia (BA), Minas Gerais (MG), Espírito Santo (ES), Rio de Janeiro (RJ), 
São Paulo (SP), Santa Catarina (SC) and Rio Grande do Sul (RS) and the numbers indicate the number of cases 
reported from each State. The five Brazilian regions are depicted in different colors and the number between 
parentheses indicate the approximated population of each region.
Figure 2. Frequency of each type of variation and molecular consequence among reported BRCA1 and BRCA2 
mutations. SNV, single nucleotide variants; LGR, large genomic rearrangements.
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restrictions that still exist for comprehensive BRCA1 and BRCA2 testing. Most of the populations where this 
strategy is used show few mutations occurring at a high frequency, often due to founder effects19,20. Thus, the 
development of such panels depends on a deep knowledge of the mutational spectrum of the target population 
and the presence of a relatively small number of recurrent mutations explaining a significant proportion of cases. 
This strategy has been proposed, for instance, for Hispanic breast and/or ovarian cancer families (with predomi-
nantly Mexican origin) where nine recurrent variants account for 53% of all detected BRCA mutations21. For this 
population, a low-cost multiplex PCR-based panel (HISPANEL) was developed and subsequently estimated to 
identify up to 75% of all true Mexican BRCA mutations. The pattern of highly recurrent mutations is also seen in 
other Latin American countries: Bahamas (six recurrent mutations correspond to 89.4% of all carriers), Colombia 
(three recurrent mutations correspond to 88.9% of all carriers) and Peru (three recurrent mutations correspond 
to 84.6% of all carriers)19. However, this striking pattern of recurrent mutations seen in several Latin American 
countries may not be observed in all countries, and specific mutations maybe be shared only by a few popula-
tions. In fact, a recent Brazilian study showed that the use of a single screening panel for different Latin American 
populations will likely not be effective22, because there does not seem to be a significant overlap of recurrent 
mutations among different Latin American populations19,23. These results are not surprising due to vary distinct 
population migration waves and therefore genetic admixture background of Brazil in comparison with the other 
Latin American countries24.
Mutations identified in one proband (N = 68; 15.4%)
Mutations identified in two 
probands (N = 25; 11.3%)
Mutations identified in three or more 
probands (N = 33; 73.4%), N and (%)
c.65T>C c.3534delC c.1A>G c.5266dupC 89 (20.2)
c.190T>C c.3544C>T c.66dupA c.3331_3334delCAAG 45 (10.2)
c.273_274delTG c.3627dupA c.244_245insA c.68_69delAG 19 (4.3)
c.302-1G>A c.3770_3771delAG c.791_794delGTTC c.211A>G 17 (3.9)
c.442-2A>G c.3967C>T c.1088delA c.5074 + 2T>C 14 (3.2)
c.450delC c.4065_4068delTCAA c.1912delG c.470_471delCT 11 (2.5)
c.514delC c.4096 + 1G>A c.2037delinsCC c.1687C>T 10 (2.3)
c.679G>T c.4117G>T c.2038_2039insCC c.4675+1G>A 9 (2.0)
c.718C>T c.4185G>A c.2389_2390delGA c.4484G>T 8 (1.8)
c.763G>T c.4327C>T c.2477_2478delCA c.181T>G 6 (1.4)
c.824_825ins10 c.4357 + 1G>A c.2727_2730delTCAA c.798_799delTT 6 (1.4)
c.833_834insA c.4357 + 1G>C c.3018_3021delTTCA c.5062_5064delGTT 6 (1.4)
c.850C>T c.4625_4626delCT c.3228_3229delAG c.188T>A 5 (1.1)
c.869T>G c.4663delA c.3257T>G c.1039_1040delCT 5 (1.1)
c.1115G>A c.4675 + 1G>T c.3403C>T c.2405_2406delTG 5 (1.1)
c.1123_1124delinsA c.4688_4694delinsG c.3640G>T c.3598C>T 5 (1.1)
c.1327A>T c.4689C>G c.3627dupA c.3817C>T 5 (1.1)
c.1340_1341insG c.4712_4716delTCTCT c.3764dupA c.3916_3917delTT 5 (1.1)
c.1471C>T c.4736_4739delCTTC c.4754_4755delCA c.4165_4166delAG 5 (1.1)
c.1504_1508delTTAAA c.4941delC c.5084_5085delTT c.4964_4982del 5 (1.1)
c.1556delA c.4987-3C>G c.5444G>A c.5177_5180delGAAA 5 (1.1)
c.1612C>T c.5095C>T c.5463_5464insT c.5251C>T 5 (1.1)
c.1789G>T c.5161delC Deletion exon 1–2 c.4183C>T 4 (0.9)
c.1823delA c.5267_5268insC Deletion exon 5–7 c.689_692delAGAC 3 (0.7)
c.1962dupG c.5445G>A Deletion exon 21–23 c.441+2T>A 3 (0.7)
c.2176_2177delCT c.5509T>C c.1039delC 3 (0.7)
c.2217dupA Deletion exon 3 c.1380dupA 3 (0.7)
c.2250dupC Deletion exon 4–6 c.1961delA 3 (0.7)
c.2331T>G Deletion exon 8 c.4287C>A 3 (0.7)
c.2722G>T Deletion exon 9–19 c.5030_5033delCTAA 3 (0.7)
c.2834_2836delinsC Deletion exon 14–16 c.5096G>A 3 (0.7)
c.2910dupA Deletion exon 16–17 c.5123C>A 3 (0.7)
c.3041T>C Deletion exon 18–19 Deletion exon 19 3 (0.7)
c.3239T>A
c.3270_3273delACCT
Table 1. Reported mutations in BRCA1, showing 126 distinct mutations identified in 441 unrelated individuals. 
Mutations in bold are novel (not described in ClinVar, BRCA Share, LOVD, ARUP or BRCA Exchange 
database) and underlined mutations were described in other database but not in ClinVar. Frequencies and 
proportions (%) in each column correspond to the fraction of each group among all BRCA1 variants identified 
(N = 441). See Supplementary Dataset for detailed information.
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Knowledge about the germline mutational spectrum among Brazilian HBOC patients is limited. Only five 
studies have performed comprehensive BRCA mutation testing (using gene sequencing and LGR analysis) to 
date25–29, corresponding to only 1,041 individuals tested, among a Brazilian population of over 207 million peo-
ple30. Most studies have focused on specific mutations, or screened only a few regions of BRCA1 and/or BRCA2 
(summarized in the Supplementary Dataset). To our knowledge, this is the largest comprehensive description of 
the spectrum of germline BRCA mutations in different geographical Brazilian regions.
Most of the mutations reported previously in smaller Brazilian studies, involving the analysis of only certain gene 
regions, have also been identified in our cohort, but it is noteworthy that some of the previously reported recurrent 
mutations are completely absent in this dataset. The most striking example is the BRCA1 ins6Kb rearrangement, 
which was reported by Esteves et al.31 in seven carriers, five of whom were from Rio Grande do Sul State. However, 
in our cohort we did not identify this rearrangement in any patient, even considering that Rio Grande do Sul was 
the second State in terms of the number of reported carriers (N = 107). The BRCA1 6 kb insertion can be detected 
by routine LGR testing through MLPA, and although we cannot assure that all probands were subjected to MLPA 
analysis, we can expect that most of them with negative sequencing results were also investigated for LGRs, since 
patients from the private healthcare setting and also those enrolled in research studies are routinely tested for LGR 
by MLPA. Indeed, a recent study from Alemar et al. reported LGR data from 351 HBOC probands from the same 
Mutations identified in one proband (N = 73; 35.1%)
Mutations identified in two 
probands (N = 12; 11.5%)
Mutations identified in three or more 
probands (N = 18; 53.4%), N and (%)
c.298A>T c.5753delA c.658_659delGT c.2808_2811delACAA 20 (9.6)
c.738delT c.5782G>T c.1337T>A c.5946delT 15 (7.2)
c.956dupA c.5800C>T c.4829_4830delTG c.156_157insAlu 11 (5.3)
c.1128delT c.5857G>T c.5164_5165delAG c.6405_6409delCTTAA 10 (4.8)
c.1238delT c.6243_6246del c.5681dupA c.2T>G 8 (3.8)
c.1588A>T c.6381_6382insTT c.7580_7583dupTAGG c.1138delA 7 (3.4)
c.1792delA c.6418_6419insTGAA c.7806-2A>G c.9382C>T 7 (3.4)
c.1796_1800delCTTAT c.6443_6444delCT c.9097dupA c.2266C>T 3 (1.4)
c.2167delA c.6468_6469delTC c.9098_9099insA c.3680_3681delTG 3 (1.4)
c.2505dupA c.6611delC c.9401delG c.4808delA 3 (1.4)
c.2701delC c.6752dupA c.9481A>T c.4964dupA 3 (1.4)
c.2845delT c.7007G>A Deletion exon 2 c.5073dupA 3 (1.4)
c.3046G>T c.7060C>T c.5682C>G 3 (1.4)
c.3195_3198delTAAT c.7180A>T c.6656C>G 3 (1.4)
c.3264dupT c.7618-2A>G c.6952C>T 3 (1.4)
c.3847_3848delGT c.7679_7680delTT c.7987delG 3 (1.4)
c.3879_3880delAT c.7738C>T c.8488-1G>A 3 (1.4)
c.3975_3978dupTGCT c.8023A>G c.9004G>A 3 (1.4)
c.4005dupA c.8195T>G
c.4006_4007insA c.8247_8248delGA
c.4131_4132insTGAGGA c.8489G>A
c.4222C>T c.8548_8551delGAAG
c.4284dupT c.8695C>T
c.4535delG c.8713delT
c.4962T>A c.8754+4A>G
c.4963delT c.8878C>T
c.4968_4969insGT c.9006delA
c.4979_4980delCT c.9076C>T
c.5158_5159insA c.9117G>A
c.5197_5198delTC c.9154C>T
c.5217_5218insA c.9282_9397del
c.5351delA c.9371 A > T
c.5351dupA c.9699_9702delTATG
c.5616_5620delAGTAA Deletion exon 13
c.5621_5624delTTAA Deletion exon 14
c.5641_5644delAAAT Deletion exon 25
c.5644_5647delTCAA
Table 2. Reported mutations in BRCA2, showing 103 distinct mutations identified in 208 unrelated individuals. 
Mutations in bold are novel (not described in ClinVar, BRCA Share, LOVD, ARUP or BRCA Exchange 
database). Frequencies and proportions (%) in each column correspond to the fraction of each group among all 
BRCA2 variants identified (N = 208). See Supplementary Dataset for detailed information.
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Brazilian State where the previous cases harboring the 6 kb insertion were reported originally, and the BRCA1 6 kb 
insertion was not detected, suggesting a very low frequency of this LGR in probands with the HBOC phenotype29.
Among all distinct mutations identified 11.8% were novel, corresponding to 4.6% of all carriers and highlight-
ing the heterogeneity of our population. The identification of novel mutations linked to HBOC is a vital informa-
tion that should be shared with established mutation databases, in order to become useful for interpreting further 
tests and to answer questions about the association between a variant and phenotype.
Overall our data show a significant molecular heterogeneity among the BRCA1 and BRCA2 mutations identified, 
and a similar profile of type and molecular consequence of pathogenic variants in both genes. In addition, BRCA1 
mutations were more frequent than BRCA2 mutations, which is in agreement with previous data showing this same 
proportion of mutations between both genes among women from different ethnicities, except Asians32. Also, similar to 
previous report33, the rate of large genomic rearrangements did not exceed 5% of all mutations. However, it is remark-
able that 34.3% of all LGR reported here correspond to the Portuguese founder mutation BRCA2 c.156_157insAlu34. 
Although significant, this frequency may still be an underestimation, since until very recently the detection of this par-
ticular mutation, which requires a specific PCR reaction, was not carried out by most commercial laboratories. Recently 
(July 2016), MRC-Holland included an extra probe that detects the wild-type sequence of this region in its BRCA2 
MLPA kits (P090 version B1 and P45 version C1), allowing the detection of this variant during MLPA testing. This sim-
ple modification is expected to increase significantly the detection rate of c.156_157insAlu in Brazilian HBOC patients. 
The probands with c.156_157insAlu identified here were from the States of Minas Gerais (1), Rio de Janeiro (3) Rio 
Grande do Sul (2) and São Paulo (5) but screening for this LGR should be done for patients regardless of State of origin.
In the current HBOC genetic testing landscape, where most laboratories have migrated to next generation sequenc-
ing (NGS), analysis workflows allow the filtering of many types of mutations, including the exclusion of synonymous 
variants. In our study, we have identified two pathogenic synonymous mutations, and this finding highlights the impor-
tance of careful evaluation of each BRCA variant detected. It is widely known that synonymous substitutions can alter 
splicing accuracy, creating or destroying a native donor or acceptor splice site, but they can also can modify translation 
fidelity, mRNA structure and protein folding35. Indeed, both pathogenic synonymous variants identified in this study 
Figure 3. Circos plot showing the distribution of all reported BRCA1 mutations. Point mutations and small 
deletions and insertions are shown around in the outermost ring, which represents the BRCA1 exons. The 
number between brackets correspond to the number of mutation carriers. Each reported LGR is represented by 
dashed blocks in the three intermediate rings, while the innermost ring represent the BRCA1 domains.
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disrupt splice donor sites, leading to exon skipping. The G nucleotide of BRCA1 c.4185G>A represents the last nucle-
otide of exon 11 (according to LRG nomenclature, formerly known as exon 12), and is conserved in 86% of the splice 
sites in mammals36. This variant lead to an aberrant transcript lacking exon 1237. Similarly, the BRCA2 c.9117G>A 
leads to a complete deletion of exon 2338 and produces a frameshift effect similar to other deleterious mutations39. The 
process of evaluating variant significance should include multiple databases, as four mutations reported here were not 
described in ClinVar, although classified as clearly pathogenic in other databases. Finally, even variants described in 
one database should have their significance confirmed in other databases, especially if classified as variants of uncer-
tain significance (VUS). As an example, using an ex vivo assay based on a splicing reporter minigene, Brandão et al.40 
demonstrated that the BRCA1 c.4987-3C>G variant leads to the skipping of exon 17. However, it remains classified as 
VUS in ClinVar and it is not reported in other databases.
In this study, we have attempted to compile pathogenic and likely pathogenic BRCA1 and BRCA2 variants identified 
in the main Genetic Cancer Risk Assessment centers in Brazil. Although this report in fact is the most comprehensive 
to date, both in number of mutations reported, as well as in number of centers/regions of the country included, many 
limitations must be considered when analyzing the results. We were unable to obtain information on the birthplace for 
most of the carriers, which would have been more informative than the center where the genetic test was performed. 
Therefore, data on geographical location should be interpreted with caution. In fact, among some of the individuals 
tested in the State of São Paulo we were able to identify residents from the Midwest States. This is not unexpected 
since the paucity of clinical and laboratory personnel trained in clinical cancer genetics in Brazil, results in a pattern of 
patients with suspected hereditary cancer being refered to testing from different parts of the country to only a few refer-
ence centers very distant from their residence place. Moreover, it might be possible that the inclusion of data from point 
mutation analysis could increase the detection and, consequently, the reporting of a few specific mutations. However, 
our data regarding the most frequently reported mutations is in agreement with previous Brazilian studies that per-
formed full BRCA1 and BRCA2 sequencing and MLPA. These studies show, for example, that the BRCA1 c.5266dupC 
is the most prevalent mutation across distinct regions of Brazil, which was also the case in our study26,27,29.
Figure 4. Circos plot showing the distribution of all reported BRCA2 mutations. Point mutations and small 
deletions and insertions are shown around in the outermost ring, which represents the BRCA2 exons. The 
number between brackets correspond to the number of mutation carriers. Each reported LGR is represented by 
dashed blocks in the intermediate ring, while the innermost ring represent the BRCA2 domains.
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We confirm that there is significant molecular heterogeneity in the BRCA1 and BRCA2 genes among Brazilian 
carriers. Although our findings suggest that this heterogeneity precludes the use of screening protocols that 
include recurrent mutation testing only, our results also show that certain mutations occur at a high frequency in 
some Brazilian regions and not others. These variations could be due to mutation founder effects, which have been 
described for other genes in Brazil. These findings should be explored in larger cohorts from specific Brazilian 
regions to assess whether in these areas, screening with a panel of recurrent mutations would be effective.
Materials and Methods
Laboratory reports of BRCA1 and BRCA2 testing showing pathogenic or likely pathogenic germline mutations 
were compiled from 28 public and private health care offices located in 11 Brazilian states, including the main ref-
erence centers for Genetic Cancer Risk Assessment (GCRA) in Brazil. Not all probands were subjected to a com-
prehensive BRCA testing (full BRCA sequencing and multiplex ligation-dependent probe amplification, MLPA). 
The genetic testing was performed using distinct methodologies, including full gene analysis by Sanger or next 
generation sequencing, point mutation analysis by Sanger or genotyping methods (as HISPANEL), and MLPA 
for analysis of large genomic rearrangements. Most data came from institutions participating in the Brazilian 
Hereditary Cancer Network (BHCN), convened by the Brazilian National Cancer Institute (INCA, Instituto 
Nacional de Cancer) and partially supported by public funding from the National Council for Scientific and 
Technical Development (CNPq)41. These centers, mostly public hospitals, are established in the Cities/States of 
Belém/Pará (in the Northern region, encompassing the Amazon basin), Salvador/Bahia (in the Northeastern 
region), Vitória/Espírito Santo, Rio de Janeiro/Rio de Janeiro, São Paulo/São Paulo, Ribeirão Preto/São Paulo, 
Barretos/São Paulo (in the Southeastern region) and Porto Alegre/Rio Grande do Sul (in Southern Brazil). In 
addition, public or private health care offices from the States of Amazonas (Northern region and the Amazon 
basin), Minas Gerais (Southeastern region), Rio Grande do Norte, Ceará (Northeastern region) and Santa 
Catarina (Southern region) also contributed with molecular data from their patients (Fig. 1). All subjects were 
unrelated and fulfilled HBOC criteria for BRCA testing. Some of the mutations described in this manuscript were 
also described in prior population/region-specific prevalence studies22,25,26,33,42–45. This project was approved by 
the Institutional Review Board from Hospital de Clínicas de Porto Alegre (approval n° 10-0521) and all individ-
uals provided written or verbal consent for BRCA testing. All methods were performed in accordance with the 
relevant guidelines and regulations, and all data supporting the results are shown in the Supplementary Dataset.
The Human Genome Variation Society (HGVS) nomenclature guidelines (http://varnomen.hgvs.org/) were 
used to annotate identified variants and the ClinVar database (www.ncbi.nlm.nih.gov/clinvar/) was used to 
determine the biological significance of all reported variants. For novel variants, BRCA Share (formerly known 
as UMD, http://www.umd.be/), LOVD (http://www.lovd.nl/3.0/home), ARUP (http://arup.utah.edu/database/
BRCA/) and BRCA Exchange (http://brcaexchange.org/) databases were also checked. Current ACMG46 guide-
lines were also used for further classification. BRCA1 and BRCA2 domains were defined using the boundaries in 
the Pfam database (http://pfam.xfam.org).
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